GlassScriptPhysician profile
Kimberly C Drummond
NPI 1043970650
$1,864.52
in general payments reported to CMS, 2019-2025
12 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $467 · 2024: $645 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $531.40 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $449.05 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $255.40 | 2022-2025 | Spravato |
| Indivior INC. | $124.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.36 | 2023-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $95.76 | 2022-2024 | Austedo Xr, Uzedy |
| Tris Pharma INC | $65.76 | 2024-2025 | Dyanavel Xr |
| Abbvie INC. | $65.39 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $64.48 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.62 | 2023 | |
| Idorsia Pharmaceuticals US INC | $27.57 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $21.89 | 2023 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Drummond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.